トリアムシノロンアセトニド
トリアムシノロンアセトニドは、ヒドロコルチゾンの約4〜10倍（一部のモデルでは最大40倍）の効力を持つ合成の中時間作用型**糖質コルチコイド**です。 **臨床上のポイントと主な特徴：** * **鉱質コルチコイド作用なし：** ヒドロコルチゾンやプレドニゾンとは異なり、トリアムシノロンには顕著な鉱質コルチコイド作用がないため、有意なナトリウムや水分の貯留を引き起こしません。 * **多様な投与方法：** 全身投与（経口、注射）、局所投与、関節内投与（特に馬のスポーツ医学において）、および病変内投与（食道狭窄や舐性肉芽腫など）に使用されます。 * **作用時間：** 経口投与の場合、代謝活性は24〜48時間持続します。しかし、筋肉内（IM）または皮下（SC）デポ注射は4〜6週間（場合によっては最大8週間）持続する可能性があり、毎日の投薬が困難な慢性炎症やアレルギー疾患に有用ですが、副腎抑制が長期化するリスクが高まります。 * **馬での使用：** 滑膜炎を軽減し、跛行を改善するために、高運動関節への関節内注射に頻繁に使用されます。競馬においてはARCIクラス4薬物に指定されています。
作用機序: Triamcinolone exerts its effects via classic genomic and non-genomic glucocorticoid pathways: 1. **Genomic Pathway:** Free triamcinolone crosses the cell membrane and binds to the cytosolic **glucocorticoid receptor (GR)**. 2. The receptor-ligand complex translocates to the nucleus and binds to **Glucocorticoid Response Elements (GREs)** on DNA. 3. **Anti-inflammatory Protein Induction:** It upregulates the expression of **lipocortin-1 (annexin A1)**. Lipocortin-1 inhibits **phospholipase A2**, thereby blocking the release of arachidonic acid from membrane phospholipids. 4. **Eicosanoid Suppression:** This → halts the synthesis of pro-inflammatory prostaglandins and leukotrienes (via COX and LOX pathways). 5. **Cytokine Inhibition:** It suppresses the transcription of major inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and reduces inflammatory cell migration and capillary permeability.
動物種別の用量
- Glucocorticoid effects · 0.25-0.5 mg PO once daily for 7 days · PO · q24h · 7 days
- Pododermatitis, feline plasmacytic pharyngitis · 2-4 mg (total dose) PO once a day or every other day 0.4-0.6 mg/kg PO once daily, then taper. · PO · q24h or q48h · Tapered
- Pemphigus complex · 0.4-0.8 mg/kg/day PO · PO · q24h
- General therapy (Tablets) · 0.11 mg/kg PO initially once a day, may increase to 0.22 mg/kg PO once daily if initial response is unsatisfactory. As soon as possible, but not later than 2 weeks, reduce dose gradually to 0.028-0.055 mg/kg/day · PO · q24h · Taper within 2 weeks
- Inflammatory, allergic, or dermatological disorders (Injectable) · 0.11-0.22 mg/kg for inflammatory or allergic disorders, and 0.22 mg/kg for dermatological disorders. · IM/SC · As needed · Effects generally persist for 7-15 days · If symptoms recur, may repeat or institute oral therapy.
- Intralesional injection · Usual dose is 1.2-1.8 mg; inject around lesion at 0.5-2.5 cm intervals. Do not exceed 0.6 mg at any one site or 6 mg total dose. · Intralesional · As needed · May repeat as necessary.
- To prevent re-stricture after esophageal dilation · Using an endoscopically directed needle, inject 0.5-1 mL of Vetalog (2 mg/mL) submucosally at time of dilation procedure. Infiltration is done circumferentially at four points around the site. · Submucosal · Once at time of procedure
- Adjunctive treatment of miliary dermatitis · 0.2-0.6 mg/kg PO once daily for 10-14 days, then tapered. · PO · q24h · 10-14 days, then taper
投与経路
禁忌
- Systemic fungal infections
- Viral infections
- Active tuberculosis
- Peptic ulcers
- Corneal ulcers
- Acute psychoses
- Cushingoid syndrome
- Idiopathic thrombocytopenia (IM administration)
- Hypersensitivity to the drug
有害事象
- Polyuria (PU)
- Polydipsia (PD)
- Polyphagia (PP)
- Weight gain
- Panting (dogs)
- Dull, dry haircoat
- Vomiting and diarrhea
- Elevated liver enzymes (e.g., ALP)
- Pancreatitis
- Gastrointestinal ulceration
- Lipidemias
- Insulin resistance / Activation of diabetes mellitus
- Muscle wasting
- Behavioral changes (depression, lethargy, viciousness)
- Iatrogenic hyperadrenocorticism (Cushing's syndrome) with chronic use
- Laminitis (horses)
薬物相互作用
- Amphotericin B · May cause hypokalemia when administered concomitantly
- Opiate Analgesics / Local Anesthetics (Epidural) · Combination in epidurals has caused serious CNS injuries and death; restrict volume to very small intrathecal test doses
- Anticholinesterase Agents (e.g., pyridostigmine) · May lead to profound muscle weakness in myasthenia gravis patients; discontinue 24h prior if possible
- Aspirin · Glucocorticoids may reduce salicylate blood levels
- Barbiturates · May increase the metabolism of glucocorticoids and decrease blood levels
- Cyclophosphamide · Glucocorticoids may inhibit hepatic metabolism of cyclophosphamide; dosage adjustments may be required
- Cyclosporine · May mutually inhibit hepatic metabolism, increasing blood levels of both drugs
- Potassium-depleting Diuretics (e.g., spironolactone) · May cause hypokalemia
- Erythromycin, Clarithromycin · May increase triamcinolone levels
- Estrogens · May potentiate the effects of triamcinolone
- Insulin · Insulin requirements may increase due to glucocorticoid-induced insulin resistance
- Isoniazid · Triamcinolone may decrease isoniazid levels
モニタリング
- Weight, appetite, signs of edema
- Serum and/or urine electrolytes
- Total plasma proteins, albumin
- Blood glucose
- Growth and development in young animals
- ACTH stimulation test if necessary
過量投与
Short-term administration of massive doses is unlikely to cause harmful effects, though one case of acute CNS effects in a dog after accidental ingestion has been reported. If acute clinical signs occur, provide supportive treatment. **Chronic Toxicity:** Chronic overdosage or prolonged use leads to serious adverse effects, primarily manifesting as iatrogenic hyperadrenocorticism (Cushing's syndrome), immunosuppression, and adrenal axis suppression.
VetSheet の薬剤リファレンスは、獣医療従事者向けの臨床意思決定支援を目的としており、専門的判断やメーカーの最新添付文書に代わるものではありません。